A lot of information you find online will discuss the marketing risks of peptides and “research use only” labeling.  But, many of the worst problems do not show up in marketing—they show up in sourcing. 

The Risk No One’s Talking About: Sourcing 

For a product to be used in humans, the active ingredient (API) must be pharmaceutical‑grade and obtained from a compliant manufacturer, with appropriate documentation like a certificate of analysis. Research‑grade or “RUO” material is not acceptable for human compounding or patient care. 

Red flags for both entrepreneurs and consumers include: 

– Products labeled “for research use only” but advertised with before‑and‑after photos, injection guides, or wellness claims. 

– Clinics sourcing injectable peptides from offshore labs, anonymous online vendors, or compounding pharmacies using bulk substances that FDA has already said should not be compounded. 

– Lack of clear documentation about the source, quality testing, and sterility of injectable products. 

For a California medspa, wellness clinic, or telehealth platform, these are not theoretical risks. They translate into potential license suspension, civil monetary penalties, product seizure, and, in extreme cases, DOJ‑led criminal investigations when patient harm or fraud is alleged. For consumers, they raise the risk of contamination, incorrect dosing, and unknown long‑term effects. 

Practical Guidance for Vendors 

Treat API like a drug, not a commodity: Work only with suppliers that are properly listed with FDA as active pharmaceutical ingredient (API) manufacturers, not generic “research labs” or trading companies, and obtain robust documentation about the products you’re purchasing. 

Draw a Bright Line on RUO (Research Use Only): Do not buy RUO‑labeled peptides for anything that will be compounded or plausibly used on patients. If you’re a seller, make sure your contracts, marketing, and communications are consistent, and maintain internal policies that any product positioned for human use must be sourced from FDA approved manufacturers. 

Maintain Records That Can Survive an Audit: Maintain documents on supplier qualifications, certifications of analysis, shipping logs, and internal quality control checks.  Map your distribution to your customers so if there is a recall or inquiry, you can show traceability within hours, not weeks. 

Don’t Let Marketing Undermine Your Sourcing Story: Make sure your public‑facing claims are consistent with your sourcing posture: if you emphasize “pharmaceutical‑grade, FDA‑registered suppliers,” be prepared to prove it.  Do not market bulk peptides as “the same as” name‑brand drugs, especially in GLP‑1 and sexual‑health categories; FDA has already signaled it will target compounded “dupes” and those who supply their APIs. 

The peptide industry is navigating a regulatory inflection point. Establishing pharmaceutical-grade sourcing practices, maintaining audit-ready documentation, and staying informed on FDA enforcement priorities are no longer optional. In an environment where federal scrutiny is intensifying and patient safety concerns are mounting, your sourcing decisions today will determine whether your business thrives—or becomes the subject of a cautionary tale tomorrow. 

—  

*This blog is intended for informational purposes only at the date of publication and does not constitute legal advice. For specific legal guidance, please consult with a qualified attorney.